Loading clinical trials...
Loading clinical trials...
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of the combination of vildagliptin, an unapproved drug, and pioglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Start Date
January 1, 2005
Primary Completion Date
January 1, 2006
Completion Date
January 1, 2006
Last Updated
May 17, 2017
527
ACTUAL participants
vildagliptin
DRUG
Lead Sponsor
Novartis Pharmaceuticals
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062